Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BANKTHIS ... do you have the link to tonight's ABC World NEWS report about the cancer treatment in China using frog venom?
I saw the news segment on ABC world news tonite. It is one of the main treatments in China producing significant positive results.
Looks like their frog venom causes apoptosis very similar to ACEL's Oncanase.
Over 30 million viewers saw this report. This should help ACEL to keep rising in the days to come and to build on today's breakout.
Thanks in advance for the link.
BTW ... that 80% strong buy rating from tradingday.com after today's close ... should also help to keep the breakout going.
Thanks for that link.
Please keep us posted.
80% Buy Rating Earned By ACEL Today
Here is the link:
http://quotes.barchart.com/texpert.asp?sym=ACEL&code=BTDY" target="_blank">http://www.tradingday.com/tbs.html?http://quotes.barchart.com/texpert.asp?sym=ACEL&code=BTDY
ACEL - ALFACELL CORP (NASDAQ)
Date Open High Low Last Change Volume % Change
03/10/08 2.25 2.39 2.20 2.38 +0.18 165688 +8.18%
Composite Indicator
Trend Spotter TM Hold
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 84319
Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 138036
Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 67% - Buy
100-Day Average Volume - 109785
Overall Average: 80% - Buy
Price Support Pivot Point Resistance
2.38 2.13 2.32 2.51
fringe...ACEL closed at $2.38 up .18 for the day!!!
The ACEL move is on!
Up 8% today.
GLTA
ACEL makes the Daily 10 Best List
Here's the link:
http://www.stock1010.com/index.php?symbol=ACEL
Too Large to copy and paste here.
This is an option grant, not an exercise. #1 of Table II shows that what is being acquired is a "right to buy".
I still think it is positive as she has negotiated for options rather than cash.
Excellent summary/opinion of the CEO's purchase
This was copied from another message board:
Re: Kuslima buys 250,000
The CEO of ACEL exercising 250,000 options at $2.18 on this past Wednesday 3-5-08 is absolutely fantastic bullish news!!!
She spent over $500,000 of her own money to exercise these shares at $2.18! This is currently the actual share price in the public market!!! This is absolutely the equivilant of buying 250,000 shares in the current public market!
This past Wednesday 3-5-08 was the first day that her options were exerciseable! They did not expire for 10 years from that date! She could have waited 10 years to exercise these options ... when the stock price is much higher sometime out in time! She did not wait ... she exercised the options right now at current market prices! This is a huge and BOLD STATEMENT OF CONFIDENCE! Virtually 100% of the time ... options are exercised only when they are at a deep discount to the current stock price ... and a big profit already exists in the difference betwee the two prices!
She knew that her huge purchase would be publicly reported ... and she did it! She spent over $500,000 of her own money to Exercise options ( Buy ACEL stock ) at the curret market price!!! What a bold and surprising and dramatic statement of confidence that ACEL's stock price will be much higher in the days to come!!!
This is the absolutely best and clear and unambiguous news that I have seen for ACEL's share price prospects in the days to come!!!
I am buying more ACEL stock on Monday!!!
What a great way to enter the weekend!
Wishing a great and relaxing weekend to all. Enjoy the dramatic news that the CEO has given to all ACEL longs ... through her bold act of confidence!!!
Kuslima Buys 250,000 Shares of ACEL - document link attached
The file is too large to copy, so here is the link to the actual filing document:
HERE IS THE LINK:
http://www.snl.com/irweblinkx/doc.aspx?IID=4104784&DID=7451162
NEWS...ACEL's CEO buys 250,000 shares at current market price of $2.18 on this past Wednesday 3-5-08!!!
This was just reported last night in the new SEC form 4 filings!
This decisive action by ACEL's CEO ... is a clear and unambiguous public statement of her strong confidence ... in ACEL's share price prospects in the days to come!
ACEL's CEO just invested over $500,000+ of her own money to purchase shares of ACEL at the current market price of $2.18!!!
Even more telling is this ... these were options she exercised at the current market price of $2.18 on 3-5-08! This was the first day they were exerciseable!!! She had 10 years left to exercise these options ... at some time in the future when the share price was higher and she had an instant profit! But she did not wait. She exercised these options on the first day that she could at the current market price of $2.18!!!
This is an extraordinary public declaration of confidence by ACEL's CEO ... in ACEL's prospects and higher stock price in the days to come!!! ACEL's CEO just invested over $500,000+ of her own money into ACEL stock at the current market price of $2.18 ... when she could have safely waited up to 10 years to exercise her options.
ACEL's CEO clearly put her own personal money ... where her own personal confidence is!!!
I am buying more ACEL on Monday.
What a fabulous weekend for all ACEL longs. Enjoy the weekend and the powerful and dramatic news that ACEL's CEO has given us ... of her unambiguous confidence in ACEL's share price prospects ... in the days to come!!!
ACEL TA
Holding the MAjor MA's nicely and bouncing off Long pSAR, Bollies tightening. Good long consolidation/accumulation under the MA21.
Starting to get that 'imminent' feeling. I like the chart here. I think it will pop nicely on Event 316 and has a good chance that it will run into Phase III completion.
ACEL's Transcript of Today's Earnings Call
Link:http://seekingalpha.com/article/67648-alfacell-corp-f2q08-qtr-end-1-31-08-earnings-call-transcript?source=yahoo
Alfacell Corp. F2Q08 (Qtr End 1/31/08) Earnings Call Transcript
posted on: March 07, 2008 | about stocks: ACEL Multiple Page ViewFont Size: PrintEmail Alfacell Corp. (ACEL)
F2Q08 (Qtr End 1/31/08) Earnings Call
March 7, 2008 11:00 am ET
Executives
Larry Kenyon - COO and CFO
Tina Shogen - CEO
Analysts
Raymond Myers - Emerging Growth Equities
Marshall Gordon - Bear Stearns
Steven Dunn - Dawson James
Arthur Barry
Donna Cossack
Mindy Rafael
Roger Bensen - Number One Corp
Presentation
Operator
Greetings and welcome to the Alfacell second quarter 2008 update conference call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions).
It is now my pleasure to introduce your host, Mr. Larry Kenyon, Chief Financial Officer for Alfacell Corporation. Thank you sir, you may begin.
Larry Kenyon
Thank you Ryan. Welcome and thank you for participating in the Alfacell Corporation fiscal second quarter 2008 update conference call for investors and analysts. As you know my name is Larry Kenyon and I am Alfacell's Chief Financial Officer and Chief Operating Officer. With me today is our Chief Executive Officer, Tina Shogen.
Tina Shogen
Good morning and thank you for being with us.
Larry Kenyon
Before we begin the presentation, please allow me a moment to read our Safe Harbor statement. This presentation includes statements that may constitute forward-looking statements usually containing the words believe, estimate, project, expect or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include the risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements the company undertakes no obligation to update these statements for revisions or changes after the date of this release. Thank you for your patience.
As we announced in today’s release as of this morning we are now at 313 evaluable events in the ONCONASE confirmatory Phase IIIb clinical trial. While we await notification that we have reached 316 evaluable events, we continue to make progress on the completion of our rolling new drug application and are preparing to begin the statistical analysis of the data once we have reached and confirmed the required number of events. To date, we have submitted all of the components of the rolling NDA that do not require statistical analysis of the clinical data.
From a commercial perspective, the fiscal second quarter was very productive as we announced our new US partnership for ONCONASE with Strativa Pharmaceuticals, the proprietary product division of Par Pharmaceutical. The deal is to generate a total of $225 million in cash milestone to Alfacell over the life of the agreement. Under the terms of the agreement, we received a non-refundable upfront license fee of $5 million and are eligible to receive a milestone payment of up to $30 million for FDA approval of ONCONASE for the treatment of malignant mesothelioma. We will also be eligible to receive up to $190 million in additional milestones in connection with the development of ONCONASE for up to three additional cancer indications and achieving certain net sales levels. Additionally, the agreement entitles us to receive double digit royalties on that sale and the ability or co-promote with support from Strativa in the future.
During the quarter, we also continued to execute on our strategy to enter into commercial relationships in key regions around the world. We now have a marketing and distribution agreement with BL&H for the commercialization of ONCONASE in Korea, Taiwan and Hong Kong. Under the agreement we received a non-refundable upfront fee of $100,000 and are eligible to receive additional cash milestone of 50% of net sales in the territory.
Our second quarter 2008 financial results met our expectations. The net loss is approximately $1.7 million or $0.04 per share, a decrease of approximately $200,000 compared to the second quarter of fiscal 2007. We did not recognize any of the non-refundable upfront fees received from Strativa or BL&H during the second quarter as revenue. These fees have been allocated to deferred revenue and will be ratably recognized as revenue when all of the general criteria for revenue recognition have been met.
The primary reason for the reduction in net loss during the quarter was the $1.2 million increase in our state tax benefit compared to fiscal 2007, which represents sales of our New Jersey state tax laws carry forwards for cash.
Second quarter 2008 R&D expenses increased by approximately $600,000, which was primarily due to increased expenses related to our preparations for completion of our rolling NDA for ONCONASE. General and administrative expenses increased by approximately $400,000 compared to the first quarter of 2007. This increase was mostly related to increased legal expenses for work done to complete our new commercial agreements during the quarter.
Cash and equivalents on January 31st, 2008 were approximately $10.2 million, an increase of approximately $4.8 million in cash and equivalents from October 31st, 2007. We estimate that our cash and equivalents will be sufficient to allow us to complete the submission of our ONCONASE NDA and beyond that take us through the fourth quarter of fiscal 2009. This estimate assumes a positive outcome for the Phase IIIb clinical trial, and that our projected costs for the completion and submission of the NDA are accurate.
Estimated cost associated with the completion and submission of our NDA are expected to increase our cash burn rate over the next few quarters, but this increase is not expected to continue beyond the planned submission of the NDA.
With that we will conclude the formal remarks and Tina and I will now take questions.
Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from the line of Raymond Myers with Emerging Growth Equities. Please go ahead.
Raymond Myers - Emerging Growth Equities
Thank you and good morning.
Tina Shogen
Good morning.
Raymond Myers - Emerging Growth Equities
Good morning, Tina. Let see, well, thank you for having another update call. I see that two more patients have past and that it continues to be -- patients continue living for quite a while. Have you drawn any conclusions about how long the patients have been living to date and whether that suggests anything about the potential efficacy of the drug?
Larry Kenyon
Ray, we haven't done any type of analysis at all at this point, and we can't really draw any conclusions. The only thing that we can comment on is that historically the survival rate for doxorubicin patients is well known and I don't think when we’ve designed this probably we would have expected to see any difference there this time around either.
Raymond Myers - Emerging Growth Equities
And from the amount of time that is taking to reach the 316 events, can we conclude that patients are living longer than you would have anticipated from the historical rates from doxorubicin.
Larry Kenyon
Frankly Ray, the only thing we can conclude is that we're at 313 events right now and we know that we will hit 316 events shortly.
Raymond Myers - Emerging Growth Equities
Okay, that's great. Now do we still expect that within about a month of reaching 316 events that you would announce top line data?
Larry Kenyon
We're hopeful of that that should be about the timeframe, yes.
Raymond Myers - Emerging Growth Equities
Okay, that's great. And I see that the research and development expense increased about 400,000 sequentially in the latest quarter, ending January. Was that primarily all for NDA submission preparations or was much of that for expanded Phase II development?
Larry Kenyon
No, it's really all related to the NDA at this point.
Raymond Myers - Emerging Growth Equities
Okay, thanks. We'll wait for that.
Larry Kenyon
Welcome.
Operator
Our next question comes from the line of Marshall Gordon with Bear Stearns.
Marshall Gordon - Bear Stearns
Hi, thanks for taking my question. Just really quickly just to review. When should we generally expect the full top line announcement of the data? Would that be within the next couple, you know, by mid-year at this point? And then the other question I had is, will you press release or communicate to the investment community in someway when you actually hit 316 events?
Larry Kenyon
Okay, Marshal. Let's start with when we hit 316 events, because that’s really the trigger for everything else in your question. The plan is, to put out a press release within 72 hours of confirming that we've hit 316 evaluable events. We will not sit on that information in anyway. So basically you can presume that as soon as we know the information and have confirmed the information the rest of the world will know. That will -- and that’s what makes it harder to pick some sort of date specific or even range for when we might have top line results because it all hinges on when we hit 316 events.
So, we're using, as a working estimate right now, that it should be approximately a month to get all of the statistical analysis completed. But do keep in mind that previous statements we may have made regarding our expectations along this line predate our relationship with Strativa. As you know with that agreement we now have a partner that is working with us on a joint development committee and a joint commercialization committee to manage the alliance. They also have an interest in the information that we will get and how we will disseminate that information and how that information get sent to the FDA eventually.
So, we've met with Strativa on timelines and trying to get started with, how to manage relationship. We're working on a number of things right now. And at this point, we don’t know if that’s going to have any impact on timelines through extra consultation and review with our partner, but it could potentially.
Marshall Gordon - Bear Stearns
Thanks.
Larry Kenyon
You're welcome.
Operator
Our next question comes from Steven Dunn with Dawson James.
Steven Dunn - Dawson James
Hi good morning, Tina and Larry, good quarter.
Tina Shogen
Good morning, Steve.
Steven Dunn - Dawson James
Just some quick housekeeping here, we are seeing rising incidences of malignant mesothelioma in mainland China, even though they had technically asbestos regulations in place, as early as from the '60s, they weren’t, but just say well enforced up until about 2001. So I guess I wanted just to confirm that the BL&H distribution agreement covers just Hong Kong and not mainland China outside the Kowloon?
Larry Kenyon
Yes. Just Hong Kong, Steve.
Steven Dunn - Dawson James
Are we in discussions with a partner to cover mainland China?
Larry Kenyon
No, we don’t comment on any of the other potential conversations we might be having. So I really can't answer that question right now.
Steven Dunn - Dawson James
All right. Why did we not use, why did we not include mainland China in to the BL&H contract?
Larry Kenyon
It was a mutual decision.
Steven Dunn - Dawson James
Okay. Just one more housekeeping, Tina, you exercised about 122,000 shares of your stock options. Did you sell any?
Tina Shogen
Absolutely not.
Steven Dunn - Dawson James
Okay.
Tina Shogen
Oh, no.
Steven Dunn - Dawson James
Okay. I think everything is covered from the previous questions and we are crossing our fingers.
Tina Shogen
All right.
Larry Kenyon
Thanks, Steve.
Tina Shogen
Thank you, Steve.
Operator
Our next question comes from [Arthur Barry], a private investor.
Arthur Barry
Good morning, Tina.
Tina Shogen
Good morning.
Arthur Barry
This week in the New York area, on the radio there was an advertisement by Novartis that they are researching Dengue fever in Singapore and that there were 50 million people who have no cure for this. It is a very, very painful disease and I know that Alfacell was doing some work with them and the company never reported what the results were, anecdotal evidence was. And I would appreciate it if you people can make a comment either now or at sometime in the near future about what actually happened with that work that was done by Novartis whether this be a positive for Alfacell or nothing happened?
Tina Shogen
Well, what we have looked at was a screening program to see whether the amphinases, in particular we're talking about, had any antiviral activity, and of course we're still looking and the number of people are looking at amphinases and as soon as the body of work is completely intent to publish. But I am very, very pleased to tell you that we certainly have some very, very impressive antiviral activity and also in Dengue fever.
Arthur Barry
Okay, thank you. That's an answer that has nothing heard before and I'm excited to hear that.
Tina Shogen
Thank you.
Operator
Our next question comes from [Donna Cossack], private investor.
Donna Cossack
Good morning, everyone.
Tina Shogen
Good morning.
Larry Kenyon
HI, Donna.
Donna Cossack
Hi, I think you've answered my question, its regarding the estimated primary completion data phase III trial, I think we covered it. I think you said within a month, am I correct?
Larry Kenyon
Well, the completion is kind of too easy of a term, getting the 316 events is -- we're not really projecting a date, but obviously I think it is safe to say that the next time we have one of these conference calls for our quarterly update, I don't think we'll be talking about when are we going to hit 316 events?
Donna Cossack
Exactly. Yeah, you've answered my question. Thank you very much.
Larry Kenyon
You're welcome.
Operator
Our next question comes from [Mindy Rafael], private investor.
Mindy Rafael
Yes, your annual report suggests that ONCONASE is 99% effective against the AIDS virus, are you planning any study to look at ONCONASE in AIDS patients?
Tina Shogen
We are not in any position to be looking at any other clinical programs at this point in time. The pre-clinical data that was reported has been published that indeed ONCONASE does have antiviral activity and especially against the AIDS virus, that again is only pre-clinically.
Mindy Rafael
Okay, thank you.
Tina Shogen
Thank you.
Operator
(Operator Instructions) We have a question from the line of Roger Bensen with Number One Corp
Roger Bensen - Number One Corp
The company does have some other clinical activity, at least as far as I know, you are looking at some trials in lung cancer and planning to go with some other esophageal and so on and so forth, what's the update on the trial that we were doing?
Larry Kenyon
Thanks Roger. That Phase I trial that we're in non-small cell lung cancer and other solid tumors is wrapping up. I think we’ve said at our last quarterly call, we reiterated it couple of times since then, until we get the NDA out of the way, we are really not planning on starting the Phase II component of those trials because of limited human resources really to accelerate, plus we also have the consideration now that with our partners, Strativa, we actually get milestones for additional cancer indications that we bring forward and we need to align with Strativa's interest, to be sure that we go into a Phase II trial that will result in Phase III trials and approvals that ultimately would lead to milestones to Alfacell.
Roger Bensen - Number One Corp
Okay. So when would we expect to have data on the Phase I trial? Generally they are pretty short in duration?
Larry Kenyon
Right, there are few patients, but I think data would be later this year assuming that enrollment completes relatively soon here.
Roger Bensen - Number One Corp
Thank you.
Larry Kenyon
Your are welcome.
Operator
(Operator Instructions) Seeing as there are no further questions, I would like to turn the call back to management for any concluding remarks.
Larry Kenyon
Thanks, Ryan. We would like to thank everyone for participating once again in our fiscal second quarter 2008 update conference call. As we have said on many occasions, Tina and I appreciate the dedication of our investors, employees and collaborators that have made it possible for us to reach this critical point in our company's history. Thank you for your loyalty and continued support. Good bye for now.
Tina Shogen
Have good day.
Operator
Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!
ACEL Q2 EARNINGS
Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
Friday March 7, 8:30 am ET
SOMERSET, N.J., March 7 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL - News) today reported its financial results for the second quarter of fiscal 2008.
ADVERTISEMENT
The company recorded a net loss of approximately $1.7 million, or $0.04 per basic and diluted common share, for the second fiscal quarter ended Jan. 31, compared to a net loss of $1.9 million, or $0.04 per basic and diluted common share, for the second quarter of fiscal 2007. The increased research and development expenses of approximately $0.6 million and general and administrative expenses of approximately $0.4 million were offset by an increase in the company's state tax benefit of approximately $1.2 million, during the second quarter of fiscal 2008 as compared to the same quarter a year ago.
Net loss for the first half of fiscal 2008 of approximately $4.4 million, or $0.10 per basic and diluted common share, represents an increase of approximately $0.1 million, compared to the $4.3 million net loss, or $0.10 per basic and diluted common share, for the first half of fiscal 2007. The increased net loss in the first half of fiscal 2008 is comprised of increased research and development expenses of approximately $0.6 million and increased general and administrative expenses of approximately $0.7 million, which were offset by increased proceeds from the sale of state tax benefit of approximately $1.2 million versus the same period in fiscal 2007.
Cash and Liquidity
As of Jan. 31, the company had cash and cash equivalents of approximately $10.2 million, an increase of approximately $4.8 million, compared to cash and cash equivalents of approximately $5.4 million on Oct. 31, 2007. The company believes that this level of cash and cash equivalents is sufficient to support its activities through the fourth quarter of fiscal year 2009, based on the current expected level of receipts and expenditures.
"We are extremely pleased with the progress made at Alfacell during the most recent fiscal quarter," said Kuslima Shogen, Alfacell's chief executive officer. "We have made considerable progress towards the completion of our rolling NDA and we have entered into key partnerships to promote and prepare for the successful commercialization of ONCONASE®."
Clinical Trials Update
Alfacell has completed patient enrollment in the confirmatory Phase IIIb clinical trial for ONCONASE (ranpirnase) in patients suffering from unresectable malignant mesothelioma. The company plans to begin the required statistical analysis of the data generated by the trial after 316 evaluable events have occurred. A total of 313 evaluable events have occurred to date.
Commercial Update
In January, Alfacell entered into two new agreements for the commercialization of ONCONASE, including:
-- an exclusive license agreement with Par Pharmaceutical, Inc. for the
commercialization of ONCONASE in the U.S. by Strativa, the branded
product division of Par. As part of the agreement, Alfacell received a
cash payment of $5 million as a non-refundable up-front fee and is
eligible to receive additional cash milestones as well as royalties on
net sales.
-- a marketing and distribution agreement with BL&H Co. Ltd., for the
commercialization of ONCONASE in Korea, Taiwan and Hong Kong. Under
the agreement, Alfacell received a $0.1 million non-refundable up-front
fee and is eligible to receive additional cash milestones and 50% of
net sales in the territory.
Conference Call & Webcast
Alfacell will host a conference call and Webcast to discuss the financial results at 11 a.m. EST on Friday, March 7. To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054. A replay of the call will be available until March 14. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 276752. A live Webcast and replay of the conference call will be available on Alfacell's Web site at www.alfacell.com.
About ONCONASE®
ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.
Safe Harbor
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in the outcome of the company's ongoing Phase IIIb clinical trial for its lead product, the company's ability to secure necessary approvals from regulatory agencies, uncertainties involving the ability of the company to finance research and development activities and its ongoing operations, potential challenges to or violations of patents, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.
ALFACELL CORPORATION
Condensed Statements of Operations
Three-Months Ended Six-Months Ended
January 31 January 31
2008 2007 2008 2007
Revenues $- $- $- $-
Expenses:
Research and
development 2,033,500 1,472,578 3,649,291 3,042,763
General and
administrative 1,473,736 1,061,743 2,645,252 1,987,781
Total expenses 3,507,236 2,534,321 6,294,543 5,030,544
Loss from operations (3,507,236) (2,534,321) (6,294,543) (5,030,544)
Interest income, net 64,807 98,539 125,314 221,826
State tax benefit 1,755,380 510,467 1,755,380 510,467
Net loss $(1,687,049) $(1,925,315) $(4,413,849) $(4,298,251)
Net loss per share-
basic and diluted $(0.04) $(0.04) $(0.10) $(0.10)
Shares used in
computation of net
loss per share:
Basic and diluted 46,861,347 44,846,064 46,645,663 44,595,902
Balance Sheet Data:
January 31, July 31,
2008 2007
Cash and cash equivalents $10,207,924 $6,968,172
Total assets $11,194,580 $7,820,499
Current liabilities $2,163,216 $1,829,900
Accumulated deficit $(96,485,604) $(92,071,755)
Total stockholders equity $3,622,340 $5,778,480
Media Contact: Investor Contact:
David Schull or Wendy Lau Timothy Engel
Russo Partners Russo Partners
212-845-4271 212-845-4242
David.Schull@russopartnersllc.com Timothy.Engel@russopartnersllc.com
Wendy.Lau@russopartnersllc.com
--------------------------------------------------------------------------------
Source: Alfacell Corporation
ACEL Golden Cross!!!
ACEL's 50 DMA($2.12) has now crossed up and over the 200 DMA($2.10) and created the very bullish Golden Cross Technical Indication!!!
ACEL now $2.15 ... looks like it can make a run to $3+ quickly. Check out ACEL's chart!
Imminent News of completion of FDA P3B trial ... any day now ... could add to the Golden Cross technical breakout ... and run the stock to $5+ quickly ... imo.
Keep your eyes on ACEL. News and action is imminent.
ACEL's earnings release and CC is tomorrow.
FDA phase P3B trial completion may be announced.
If yes ... stock could run off of the news.
Appears that ACEL Clinical Trials Are Not Being Updated
This has been copied from another message board:
Every day that I have been monitoring the clinicaltrials website, the clinical trials for Onconase has been updated every day without fail.
The last update is now showing as 2/29/2008.
Here is the link:
http://clinicaltrials.gov/ct2/show/NCT00003034?term=ONCONASE&rank=1
IMO... News is Imminent.
ACEL conference call scheduled for March 12 has been moved up to Friday March 7. Speculation is that they've got something to say....
I'm seeing a triple play on ACEL...The chart and TA looks great, major news is imminent, and as it moves up the shorts will have to cover...my read is strong buy here...
ACEL News
Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
Feb 29, 2008 8:30:00 AM
SOMERSET, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it will host a conference call and Webcast at 11 a.m. EST on Friday, March 7. During the call, Kuslima Shogen, Alfacell's chief executive officer, and Lawrence A. Kenyon, chief operating officer and chief financial officer, will present an overview of Alfacell's financial performance for the fiscal second quarter 2008, ended January 31, 2008.
To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054. A replay of the call will be available until March 14. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 276752. A live Webcast and replay of the conference call will be available on Alfacell's Web site at www.alfacell.com.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.
Safe Harbor
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Media Contact: Investor Contact:
David Schull or Wendy Lau Timothy Engel
Russo Partners Russo Partners
212-845-4271 212-845-4242
david.schull@russopartnersllc.com Timothy.Engel@russopartnersllc.com
wendy.lau@russopartnersllc.com
SOURCE Alfacell Corporation
COVER STORY - ACEL'S ONCONASE
APRIL ISSUE OF DRUG DISCOVERY & DEVELOPMENT
LINK TO SUBSCRIBE TO THE ARTICLE:
http://www.dddmag.com/DDD-upcoming-issues.aspx?menuid=54
April, 2008 Issue
Discovery
COVER STORY
Beating Drug Resistance: Cancer Drugs
Drug resistance is a major impediment to successful strategies for cancer therapy. New tools for gene expression profiling are now converging with the world of small non-coding RNAs (ncRNAs). Strategies to overcome drug resistance will be reviewed generally and with respect to Onconase (ranpirnase) from Alfacell.
Data Mining
This article outlines some of the issues with safety data and describes some data mining methods that address challenges. Statistical data mining models include hierarchical generalized linear models and inside-out machine learning models. Graphical analysis and reporting also is covered.
Development
Advances in HIV Drug Development
Senior editor James Netterwald will discuss current and emerging HIV treatment modalities. Special focus will be placed on emerging HIV treatments that utilize new strategies including new targets, new drug delivery options, and combination therapies.
Insect Bioreactors
Senior editor James Netterwald will discuss how insect cells are used to product biopharmaceuticals. Types of cells, bioreactor vessels, conditions, and new drugs developed in insect bioreactors will be the described in detail.
Genomics and Proteomics
MS vs. NMR for Protein Analysis
This article will discuss the pros and cons of using NMR or MS for protein analysis. Issues such as sensitivity of these methods and how bioinformatics is used to organize data resulting from them will be addressed in the context of proteomics research.
Real-time qPCR
This article discusses how preparation of RNA can affect qPCR results. Current RNA sample prep technologies are discussed. Examples illustrate the strengths and weaknesses of each technology with regard to the effects of RNA sample prep on qPCR.
Industry Issues
Building a Better Drug: New Development Strategies
For those suffering from migraine pain, relief cannot come soon enough. TorreyPines Therapeutics’s Tezampanel has completed Phase IIb clinical trials, representing the first novel treatment option in more than a decade. The company will discuss its strategy of developing versatile product candidates capable of treating a number of different diseases and disorders.
Departments
Technology Advances
Contributing Editor Mike May will discuss advances in Chemistry.
Policy & Projections
Contributing Editor Ted Agres will examine current issues before Congress and pending FDA regulations.
Short Interest Post on ACEL
from another board regarding the Latest Short Interest News:
Re: Feb. mid-month short interest up 24%; highest number in last 12 months
Wow!!! ... This Massive short interest is incredibly bullish !!!
Shorts have sold over 400,000 more shares short in the last one month up to 2-15-08. Clearly explains fall in price from $2.69 to $2.10 during that 30 days.
As of 2-15-08 there are over 2.1 million short shares.
Any move up in price ... and they need to start covering. Combined with the extreme oversold technical indicators ... calling for a move back up ... we can get an explosive move to the upside ... which can then really take-off North by triggering a fast short squeeze ... where ever-incresing numbers of shorts ' rush to cover.
I did not expect this " sharply increased short interest " bonanza to fall into our laps here.
With a positive PR on completion of P3B FDA trial imminent ... any possible day now ... a potentially explosive move to the upside is very possible in the days to come.
And ... all of the technical analysis indicators are now screaming ... " Buy...Buy...Buy"!
Wow ... it is surely going to be very interesting from here ... in the immediate days to come
Latest Short Interest Numbers on ACEL
from another board -- This is very bullish...
Feb. mid-month short interest up 24%; highest number in last 12 months
Alfacell Corporation - Common Stock
Settlement-Date Short-Interest Percent-Change Average-Daily-Share-Volume Days-to-Cover*=
02/15/2008-------- 2,105,283--------- 24.08------------ 113,982-------- 18.47
01/31/2008-------- 1,696,745--------- 14.08------------ 279,088-------- 6.08
01/15/2008-------- 1,487,272--------- (0.02)------------ 85,289-------- 17.44
12/31/2007-------- 1,487,622--------- (1.64)------------ 84,944-------- 17.51
12/14/2007-------- 1,512,377--------- (1.14)------------ 84,988-------- 17.80
11/30/2007-------- 1,529,747---------- 6.65------------- 71,526-------- 21.39
11/15/2007-------- 1,434,400--------- 1.62-------------- 87,846-------- 16.33
10/31/2007-------- 1,411,509--------- (12.82)----------- 80,821------- 17.46
10/15/2007-------- 1,619,007---------- 3.18------------- 91,246-------- 17.74
09/28/2007-------- 1,569,074--------- 8.04-------------- 134,310 -------11.68
09/14/2007 --------1,452,293--------- (10.65)------------ 157,839------- 9.20
08/15/2007-------- 1,625,397---------- 6.39 -------------119,589-------- 13.59
07/13/2007-------- 1,527,800--------- 9.21--------------- 211,324-------- 7.23
06/15/2007-------- 1,398,900---------- 30.10------------- 250,187-------- 5.59
05/15/2007-------- 1,075,290--------- 150.50------------- 790,671-------- 1.36
04/13/2007-------- 429,256------------ 46.23------------- 374,362-------- 1.15
03/15/2007-------- 293,551----------- (31.85)-------------- 74,251------- 3.95
The Chart Is Turning Around Nicely
Money flow is going positive, as are the Momentum indicators. Won't be long now.
Link back one post in this thread for the chart.
fringe
that is possible ,as in plausable. the overall market is looking not-so-bad since the Fed is making the right moves.
Onc is going to be approved since its a safe drug .
Plus the Fda can't be negative on every new drug there is! Law of Averages says yes to approval. 10.00 this yr is possible , much higher later.
Thanks for your price-target projections on ACEL.
If it does one-fourth of what you are expecting from here ... it will be a 500% return from here. From your lips ...
I'm looking for fringe's latest TA read soon. Should be interesting.
That excellent 80% Technical Analysis Buy Rating from tradingday.com ... posted here by another poster last night is powerful. It has a great track record and credibility. You can put 20 of your favorite stocks in that link ... and you will be fortunate to get even one with up to a 50% Buy Rating. That 80% TA Buy rating for ACEL is great. Hit that link in last nites post ...and put some of your stocks in ... and see for yourself.
What are other readers here seeing?
Hey fringe, what's your latest read on ACEL...where do you think it can go on the imminent annoucement of the 316th event assuming that included in that PR will be mention of ACEL moving forward with the NDA?
skyyy...if ONCONASE gets FDA approval ACEL is a $40 stock. Take a look at Acorda Therapeutics (ACOR)...in the fall of 2006 over a three month period that stock ran from $2 to $27 on the PR of the completion of the final phase of the FDA trials. ACOR is currently trading at $22 and still doesn't have FDA approval! On top of that the market for ONCONASE is much larger than the MS drug for ACOR. My read for ACEL is that we will see three levels in the stock in the coming 10-12 months. Upon the announcement of the completion of their phase IIIb trials (or rather reaching the 316th event which will allow the analysis of the statistical data to begin) IMO we'll see a new 52-week high ($3.74) and I've seen projections to $4.50...this news is imminent. IMO the stock will build to $7-$10 on the anticipation of positive results from the analysis of the statistical data which will take three to four months. Again, IMO, the results will be very strong and that announcement will shoot ACEL to $15-$20 conservatively. Why do I think the results will be very strong: 1)the completion of the 316th event is taking much, much longer than anybody expected which means subjects using ONCONASE are living much longer than the control group and than expected; 2) Sidransky wouldn't put his reputation on the line by becoming chairman of the board (announced in late January) at this particular time if he wasn't convinced that the results will be exciting and warrant FDA approval; 3) ACEL wouldn't be receiving major distribution deals for multi-millions and announcing them without being extremely confident of the results...the fact is, they know what the results are going to be, IMO, because the final four or five events will not substantively change the outcome. So when ACEL receives FDA approval in less than a year from now, it puts all of their deals, some of which are probably yet to be announced, into motion and the guaranteed income alone will create earnings of $1-$2/share (probably more when new deals are included). Based on that and using a PE of 30 ACEL is $40-$60. skyyy, sorry for the long post, but you asked......
Excellent 80% Buy Rating Reported
This was copied & pasted from another board:
Excellent 80% Buy Rating Reported
Do your own DD; check out the charts and buy and sell signals for ACEL in Tradingday.com.
This is a comprehensive, technical analysis of Alfacell.
Link: http://quotes.barchart.com/texpert.asp?sym=ACEL&code=BTDY" target="_blank">http://www.tradingday.com/tbs.html?http://quotes.barchart.com/texpert.asp?sym=ACEL&code=BTDY
ACEL - ALFACELL CORP (NASDAQ)
Date Open High Low Last Change Volume % Change
02/26/08 2.11 2.38 2.08 2.38 +0.27 99238 +12.80%
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold
Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 117527
Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 134623
Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 67% - Buy
100-Day Average Volume - 109362
Overall Average: 80% - Buy
Price Support Pivot Point Resistance
2.38 1.98 2.28 2.58
igot...the next leg up for ACEL has started. ACEL closed up 12.8% at $2.38 today. Great call by you yesterday in your post that it was a strong buy. Now up 12.8% in one day since your post.
The PR of completion of FDA trial is imminent now. Could be any day. Looks like the move up in anticipation started today.
IMO ... stock will quickly pop over $4+ on the coming PR. A short squeeze should be triggered on any move above $2.75 or so. There are 1.7 million short shares that must rush to cover ... by buying shares in the open market ... to prevent a wipe-out in a strong move up. IMO...the coming PR will likely trigger the short squeeze.
An additional suprise PR ... such as new investment firm coverage or a new foreign rights licensing deal... would really make things exciting.
Any thoughts to share here? What are your projections if ONCANASE gets FDA approval by EOY?
ACEL ($2.19) now. Bid-$2.19 & Ask-$2.20
PR can happen any day now.
fringe...ACEL is moving up nicely here.
The P3B FDA trial conclusion PR should be announced any day now. It held the 200DMA nicely. Looks like its beginning to move up in anticipation of coming news soon.
What is your TA read at this point?
Take a look at Sidransky's other company Champions Biotech. IMO this is a great re-entry point or buying opportunity for CSBR...with that tight float it's poised to take off on some good news which seems to be overdue...
ACEL is a great buy here....it's way over sold and huge news on the conclusion of Phase IIIb trials is due any day...IMO it bursts through three bucks on the iminent news....
Let's not forget about Amphinase - the second RNA
This has been copied from another message board.
ACEL's other anti-cancer product:
link: http://www.bio.org/splice/20070629.asp
The Frog Prince and His Latest Molecule
Printer Friendly
June 22, 2007
Structure of the Amphinase molecule isolated from the leopard frog.
credit: University of Bath
A princess was walking in the woods with her golden ball, tossing it in the air until it fell into a deep spring. "Alas! if I could only get my ball again, I would give all my fine clothes and jewels, and everything that I have in the world," wailed the princess in the Brothers Grimm fairy tale, "The Frog Prince." Of course the princess got her ball back with the help of the frog prince. That story was first published around 1812 in Germany by the Brothers Grimm. Today, there are people with cancer who would do anything for help. And as the frog prince helped the princess so may the leopard frog help future generations of cancer patients.
Research published this week in the Journal of Molecular Biology by scientists from the University of Bath (Bath, U.K.) and Alfacell, a biotechnology company in New Jersey (U.S.) describes a new molecule found in the egg cell of the amphibian, the leopard frog. The molecule, aptly named Amphinase, exerts it's cancer-killing power by recognizing the sugars on the surface of the tumor cell, binding to the cell surface, and inactivating its RNA. The end result, a dead tumor cell.
The researchers say that although Amphinase could be used as a treatment for many forms of cancer it offers the most hope for treating brain tumors, for which surgery and chemotherapy are the only treatment options.
"It is rather like Mother Nature's very own magic bullet for recognizing and destroying cancer cells." says Ravi Acharya, one of the researchers in the U.K. "It is highly specific at hunting and destroying tumor cells, is easily synthesized in the laboratory and offers great hope as a therapeutic treatment of the future," he adds.
The researchers say that Amphinase is in the very early stages of development. That is, several years and many trials away from being developed into patient treatment.
Alfacell is now working on pre-clinical trials of Amphinase. Amphinase is the second RNA - attacking, anti-tumor molecule isolated by Alfacell from leopard frog egg cells. The first, Onconase, is currently in clinical trials for mesothelioma, non-small lung cancer and other solid tumors.
Rana pipiens, the leopard frog
Refresher for ACEL 's Onconase (Ranpirnase):
copied and pasted from The Mesothelioma Center web site:
Link: http://www.mesotheliomacenter.org/mesothelioma-news/2007/04/16/preclinical-data-show-alfacells-onconase-inhibits-tumor-growth-of-non-small-cell-lung-cancer-breast-cancer-cells/
Home » Alfacell, Drug Companies, Full Archive, Novel Treatments & Drugs, Onconase (ranpirnase) » Preclinical Data Show Alfacell’s Onconase® Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
Preclinical Data Show Alfacell’s Onconase® Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
Monday, April 16th, 2007.
Alfacell Corporation today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that Onconase (ranpirnase) significantly inhibits tumor growth of non-small cell lung cancer (NSCLC) and breast cancer cells.
In the poster titled “Increased apoptosis and reduced lactate levels by ranpirnase in human lung and breast cancer”, Intae Lee, Ph.D. and collaborators at the University of Pennsylvania demonstrated that Onconase significantly inhibited tumor growth by inducing apoptosis (cell death) in A549 and NCI-H1975 human NSCLC cells and MDA-MB-231 and MCF-7 human breast cancer cells without damaging non-cancerous cells such as HLF-1 human lung fibroblast and NCI/3T3 fibroblast. Additionally, the data indicated that twice weekly injections of Onconase were more effective than an equivalent single dose injection in these tumor types.
“The findings of our investigation suggest important potential clinical uses of Onconase for the treatment of NSCLC and breast cancer,” said Dr. Lee.
Kuslima Shogen, Alfacell’s chairman and chief executive officer, added: “This research adds to the extensive published data that supports our continued development of Onconase for multiple cancer indications. The Onconase franchise includes the gateway indication of malignant mesothelioma and several other tumor types for which we are continuing preclinical and clinical studies.”
About Onconase®
Onconase is a first-in-class therapeutic product candidate based on Alfacell’s proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, Onconase has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. Onconase triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, Onconase, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of Onconase in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.
This news on ACEL is strong....I've noticed that they usually make announcements in bunches....maybe more news is on the way.....of course, we know the 316th "event" should be any day....anybody have an idea where it could go if ACEL announces after the 316th event that they will apply for a new drug app(NDA)?
Great News Release by ACEL today...fringe. These findings presented today bode very well for ONCANASE'S future.
From this point on ... additional positive PR's regarding ONCANASE ... seem imminent. The conclusion of the big P3B FDA trial with the PR announcement of the 316th event ... could be announced any day now. Final work on the completion of the NDA for filing with the FDA should begin with that announcement.
BTW ... ACEL's ibox is looking great with all of your recent updates. Many thanks.
Things should get pretty exciting here ... from here on in.
NEWS
Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
Feb 21, 2008 8:30:00 AM
View Additional Profiles
SOMERSET, N.J., Feb. 21 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that in vitro and in vivo data presented at the 5th Cancer Drug Research & Development conference show the genes affected and biological pathways impacted by ONCONASE stimulated intracellular events as revealed by expression profiling of human malignant mesothelioma cell lines. Data presented also show that ONCONASE conjugates effectively kill human cancer cells in cell culture and murine models of cancer.
Susanna Rybak, Ph.D., a member of Alfacell's scientific advisory board, presented a poster entitled "ONCONASE (ranpirnase): Intracellular Activity and Extracellular Selectivity." The data demonstrated that 181 genes were consistently up- and down-regulated by ONCONASE and that the genes involved in triggering apoptosis (programmed cell death) and the intracellular MAPK signaling pathway were impacted by ONCONASE in vitro. Additionally, pre-clinical data in mice demonstrated the relative potency of chemical conjugates of ONCONASE. These findings further support the research of next generation targeted ONCONASE fusion proteins in an effort to develop compounds with improved tumor penetrating abilities. The research was conducted in collaboration with Alfacell at Fox Chase Cancer Center and the University of Duisburg-Essen.
"This work may explain the intrinsic anti-tumor activity seen after ONCONASE treatment through the identification of the specific genes affected and the biological pathways impacted," said Dr. Rybak. "Additionally, this data is helping us to better understand the optimal intracellular pathways for developing antibody targeted ONCONASE compounds."
"The data presented further illuminates the potential for ONCONASE to simultaneously switch on and off numerous genes controlling major regulatory processes in the cell life cycle, and underscores that ONCONASE works selectively and does not appear to kill cells indiscriminately," added Kuslima Shogen, Alfacell's chief executive officer. "This research represents an important step forward in our continuing efforts to create targeted ONCONASE fusion proteins and to bring them forward into the clinic."
About ONCONASE(R)
ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of
ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.
i tend to agree with you're post!!!!!!!!!!!!!!
i am choosing not to post so much anymore ,well when we get big pops i most certainly will.
GLTA
It's been three weeks since ACEL announced 311 "evaluable events"...at that time only five out of 117 to go to reach the necessary 316...seems like big news could be any day...this final phase of the trials has taken longer than expected; that must mean patients are living longer...
TA Update
The PPS is firmly perched on the MA200 while everything around it consolidates. pSAR is coming down to say 'hello' now.
It's going to need news to turn the trends around. The chart may be foretelling same here.
I have put a Fast Aroon in here to give us a better sense of trend change possibilities.
fringe
fringe...
Can you put the 2 PR's referenced to ... in the 2 posts just prior to this one in the ibox?
One is the PR of Dr. Sidransky recently becoming Chairman of ACEL.
The other is the recent licensing partner PR for USA distribution rights to ACEL's Oncanase drug ... which got ACEL the recent $5 million up-front payment.
These two PR's are must see DD for all newcomers that will be coming here.
As always ... many thanks.
BTW ... ACEL looks like it is holding up very well at $2.24 ... above the 200DMA at $2.13 now. All of the lower moving average are moving up nicely. The 50DMA at $1.97 now looks like it will cross above the 200DMA in a week or so if the trends hold up.
What is your TA read at this point in time now?
Thanks in advance.
Thanks for posting the PR that Dr. David Sidransky has become Chairman of ACEL. He is one of the true world-reknowned giants in the search for a cure to cancer. He is on the board of Imclone as well as many other pharma players. His support of Carl Icahn ... allowed Icahn to gain control of Imclone. His relationships in Biotechnology are world class.
Great news for ACEL investors here IMO. Dr. Sidransky agreeing to become Chairman prior to FDA decision soon to come ... bodes well for eventual FDA approval later this year IMO.
Fringe... can you put this PR on Dr. Sidransky as ACEL chairman in the ibox?
Thanks for the PR on ACEL's licensing partner for USA distribution rights. The nice $5 million up-front payment to ACEL ... shows that the pharma partner believes that FDA approval will come.
fringe ... can you put this PR in the ibox? This is major news and DD to newcomers here.
WHERE TO BUY ONCONASE
where to sign up ACEL ONCONASE:
Link to sign up:
http://www.drugsreport.co.uk/onconase.php
Sorry for the link, but the site would not paste properly.
Wonderful Testimony Regarding the Drug.
Onconase is actually saving lives.
This ACEL article is from another board.
Inspiring Blog from a patient in the Onconase trial
http://www.mesothel.com/profiles/douglas.htm
Sorry for the link. The article is too large to paste.
New Investment Firm Coverage?
This is from another board:
New Investment Firm Coverage:
With the recent licensing deals, DR.Sidransky's appointment as Chairman, articles, and short time-table for coming events ...it seems likely that management and DR. S. are talking to new investment firms to begin coverage on ACEL.
With DR S.'s top contacts from his board and medical positions and relationships ... this could include some pretty big names.
A Google search of Dr. S's positions and relationships is very impressive. Just look at the investment players that he is closely associated with as fellow board members and advisors.
It seems likely that one of the major reasons that Dr. S. became Chairman recently ... is to bring some new investment firm coverage for ACEL. Speculation is that new investment firm coverage could be one of the imminent PR's to come.
Anyone here knowledgeable about any of the firms and/or broker/dealers that specialize in this specific space? Perhaps some of Imclone's coverage has been contacted through the various relationships.
Very interesting possibilities here. Any thoughts or insight?
Dr. S. and his various relationships are probably the key.
A massive "short-squeeze" will likely be triggered when ACEL's share price approaches $3.
Any of the imminent press releases we are all awaiting from ACEL should easily move the stock up towards $3 and trigger the squeeze.
1.7 million short/shares forced to cover should pop the stock to $5+ ... once the squeeze is triggered.
Which PR will come first? All thoughts and insight here are appreciated in advance.
Will it be the announcement of the completion of the P3B FDA trial?
New licensing rights for additional foreign markets?
New partnerships for Amphinase and additional indications for Oncanase ... such as the speculations about possible discussions/negotiations with Imclone ... of which Dr. Sidransky is also a board member ... who backed Mr. Icahn's takeover of Imclone?
Which PR comes first and how fast is debateable. The coming massive "short-squeeze" is a matter of time.
Smart shorts will begin to cover now ... before they are forced to do so in a panic squeeze.
From here on ... it gets very exciting.
A massive "short-squeeze" will likely be triggered when ACEL's share price approaches $3.
Any of the imminent press releases we are all awaiting should easily move the stock up towards $3 and trigger the squeeze.
1.7 million short/shares forced to cover should pop the stock to $5+ ... once the squeeze is triggered.
Which PR will come first? All thoughts and insight here are appreciated in advance.
Will it be the announcement of the completion of the P3B FDA trial?
New licensing rights for additional foreign markets?
New partnerships for Amphinase and additional indications for Oncanase ... such as the speculations about possible discussions/negotiations with Imclone ... of which Dr. Sidransky is also a board member ... who backed Mr. Icahn's takeover of Imclone?
Which PR comes first and how fast is debateable. The coming massive "short-squeeze" is a matter of time.
Smart shorts will begin to cover now ... before they are forced to do so in a panic squeeze.
From here on ... it gets very exciting.
More good news on ACEL short interest
This is also from another board:
Re: Short interest up again - Explanation?
IMO ... the stock price needed to run up a little more than it did in its recent move-up to $2.69/share ... in order to set-off the beginning of the big "short-squeeze".
A "short-squeeze" ends up feeding on itself. The more that shorts begin buying stock to cover their shorts ... then the remaining shorts are forced to also buy stock in order to prevent a slaughter to themselves.
IMO ... we need to pop a little higher to set-off the squeeze. The next move-up should do it.
Smart shorts would slowly begin to start covering now ... in order to prevent "a mad dash to buy" to cover shorts ... in the big short-squeeze to come. IMO ... the next short-term move-up will trigger a short-squeeze that will propel the share/price to at least $5 on that short-time move alone.
It is surprisingly good news now ... to realize that ACEL still has 1.7 million shares/short ... even after the quick move from $1.45 to $2.69 recently. We have a ton of "short fuel" on hand to fuel the next move up in price.
Short Interest Commentary
This is also from another board:
1.7 million "short shares" as of 1-31-08 is great news. That means that 1.7 million shares of ACEL need to be bought by those short ... to cut their losses on the next pop up.
I would have quessed that less than 300,000 "short shares" were left after the recent run from $1.45 to $2.69.
The big "short squeeze" will come on the next move up. The imminent PR announcement of the 316th event ... or any move above $2.40 will set-off the big "short-squeeze" coming. The panicky rush to buy 1.7 million shares of ACEL to cover "shorts" and prevent deeper "short" losses will likely create trading days with over one million shares/day of volume.
The next PR should do it. Any chance of a new foreign rights deal or something else before the PR of the conclusion of trial?
Any thoughts/guesses on schedule likelihood for next PR?
Latest Short Interest on ACEL
This is from another message board:
Short interest up again
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to cv
01/31/2008 1,696,745 14.08 279,088 6.08
The avg. vol. and therefore days to cover are wrong. You wonder how that happens.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
159
|
Created
|
10/22/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |